-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on Caris Life Sciences, Raises Price Target to $25

Benzinga·11/10/2026 12:53:37
Listen to the news
Piper Sandler analyst David Westenberg maintains Caris Life Sciences (NASDAQ:CAI) with a Neutral and raises the price target from $22 to $25.